{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-016423","form_type":"8-K","ticker":"ZBH","cik":"0001136869","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.033347+00:00","generated_at":"2026-06-16T02:40:52.624474+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zimmer Biomet Q1 net sales $1.831B (+10.1% reported, +13.2% CC); raises FY2023 guidance","bullets":["Q1 diluted EPS $1.11 GAAP, adjusted $1.89; net earnings $232.5M GAAP, $396.8M adjusted.","U.S. knee sales $448.2M (+18.1% YoY); hip sales $252.3M (+12.3% YoY).","Raises FY2023 adjusted EPS guidance to $7.40-$7.50 (prior $6.95-$7.15); reported revenue growth 5.0-6.0% (prior 1.5-3.5%).","Completed acquisition of Embody, Inc., adding collagen-based biointegrative solutions to sports medicine.","Launched Persona OsseoTi Keel Tibia for cementless knee replacement; ZBEdge platform enhancements at AAOS 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-016423","json":"https://secwatch.observer/filing/0000950170-23-016423.json","markdown":"https://secwatch.observer/filing/0000950170-23-016423.md","text":"https://secwatch.observer/filing/0000950170-23-016423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/zbh-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:40:52.624474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9be9e94e5275afc8f5241ec3062c59175bda8e10","claim":"ZIMMER BIOMET HOLDINGS, INC. reported first quarter ended March 31, 2023 results: revenue $1.831 billion, net income $232.5 million, EPS $1.11.","evidence_excerpt":"The Company reported first quarter net sales of $1.831 billion, an increase of 10.1% over the prior year period, and an increase of 13.2% on a constant currency 1 basis. Net earnings for the first quarter were $232.5 million, or $396.8 million on an adjusted 1 basis. Diluted earnings per share were $1.11 for the first quarter, and adjusted 1 diluted earnings per share were $1.89.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$1.831 billion"},{"label":"Net income","value":"$232.5 million"},{"label":"EPS","value":"$1.11"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b15dc276af8f61be2fb4d8dbe12b5c9639aa8d11","claim":"ZIMMER BIOMET HOLDINGS, INC. reported full-year 2023 results: EPS $7.40 - $7.50. Guidance raised.","evidence_excerpt":"Projected Year Ending December 31, 2023 Previous Guidance Updated Guidance 2023 Reported Revenue Change 1.5% - 3.5% 5.0% - 6.0% Foreign Currency Exchange Impact (1.5)% (1.0)% Adjusted Diluted EPS (1) $6.95 - $7.15 $7.40 - $7.50","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"EPS","value":"$7.40 - $7.50"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}